Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;10(3):565-580.
doi: 10.1007/s40123-021-00351-4. Epub 2021 Jun 12.

Noninfectious Intermediate, Posterior, or Panuveitis: Results from the Retrospective, Observational, International EyeCOPE Study

Michal Kramer  1 , Michaela Brichova  2 , Ilknur Tugal-Tutkun  3 , Mykola Panchenko  4 , Natali Gormezano  5 , Franziska Koenigsbauer  6 , Pablo Franco  7 , Cristina Muccioli  8 , Murat Hasanreisoglu  9 ; International EyeCOPE Study Group
Collaborators, Affiliations

Noninfectious Intermediate, Posterior, or Panuveitis: Results from the Retrospective, Observational, International EyeCOPE Study

Michal Kramer et al. Ophthalmol Ther. 2021 Sep.

Abstract

Introduction: The EyeCOPE study characterized noninfectious intermediate posterior, or panuveitis (NIIPPU) before biologic agents were widely available.

Methods: This retrospective, observational study included adults with NIIPPU attending a routine ophthalmological visit. Data were collected from the study visit and medical records.

Results: Of 565 patients, 58.8% were female, and the mean age was 41.3 years; 33.8% had idiopathic uveitis and 45.8% had panuveitis. The median time from symptom onset to diagnosis and treatment was 27.0 and 30.5 days, respectively. Patients received immunosuppressants and systemic/local corticosteroids. Most patients experienced substantial decline in ocular function (mean best corrected visual acuity, 0.4 logMAR). Mean total work productivity impairment among employed patients was 31.0%. Most patients reported ocular complications (70.8%) such as vision loss and cataracts.

Conclusions: Despite treatment, most patients with NIIPPU experienced a decline in ocular function and ocular complications. There is an unmet need for additional NIIPPU treatment, such as targeted monoclonal antibodies.

Keywords: Corticosteroid disease burden; Disease characteristics; Immunosuppressants; Noninfectious uveitis; Patient-reported outcomes.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Summary of AC cell gradea (a), VH gradeb (b), and presence of active inflammatory chorioretinal and/or inflammatory retinal vascular lesionsb (c). MAS population with left (n = 559) and right (n = 558) eye. Patients with valid data were included and percentages were calculated based on non-missing values. aMissing data from one left eye. bMissing data from two left eyes. AC anterior chamber, MAS main analysis set, NEI National Eye Institute, SUN Standardization of Uveitis Nomenclature, VH vitreous haze
Fig. 2
Fig. 2
Summary of treatment patterns in NIIPPU patients (MAS population). Systemic therapies (a) and topical and injectable corticosteroid therapies (b). Methods of application were eye drops, subtenon and subconjunctival injection, intravitreal injection, and intravitreal implant. Prednisone was used as topical only. Participants previously using systemic therapies, n = 565; local corticosteroid therapies, n = 565. Participants currently using systemic therapies, n = 565; local corticosteroid therapies, n = 565. a“Other” includes immunosuppressants (including immunobiologicals, e.g., monoclonal antibodies), corticosteroids for systemic use, immunostimulants, anti-inflammatory and anti-rheumatic products, anti-anemic preparations, anti-diarrheals, intestinal anti-inflammatory/anti-infective agents, anti-gout preparations, ophthalmologicals, anti-bacterials for systemic use, drugs for acid-related disorders, anti-neoplastic agents, and anti-protozoals. b“Other” includes ophthalmologicals (prednisolone acetate, triamcinolone acetonide, triamcinolone, fluorometholone, betamethasone diproprionate, betamethasone and chloramphenicol, loteprednol etabonate, prednisolone, rimexolone, dexamethasone, loteprednol, difluprednate, betabioptal, dexamethasone sodium phosphate, methylprednisolone acetate). MAS main analysis set; NIIPPU noninfectious intermediate, posterior, or panuveitis
Fig. 3
Fig. 3
Summary of ocular complications in NIIPPU patients. Patients with previous ocular complications, n = 439. Patients with current ocular complications, n = 400. MAS main analysis set, NIIPPU noninfectious intermediate, posterior, or panuveitis
See this image and copyright information in PMC

References

    1. Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature Working Group Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–516. doi: 10.1016/j.ajo.2005.03.057. - DOI - PMC - PubMed
    1. Deschenes J, Murray PI, Rao NA, Nussenblatt RB, International Uveitis Study Group International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul Immunol Inflamm. 2008;16(1):1–2. doi: 10.1080/09273940801899822. - DOI - PubMed
    1. Zierhut M, Deuter C, Murray PI. Classification of uveitis – current guidelines. Eur Ophthalmic Rev. 2007;77–8.
    1. Read RW. Uveitis: advances in understanding of pathogenesis and treatment. Curr Rheumatol Rep. 2006;8(4):260–266. doi: 10.1007/s11926-006-0006-6. - DOI - PubMed
    1. Karkhur S, Hasanreisoglu M, Vigil E, et al. Interleukin-6 inhibition in the management of non-infectious uveitis and beyond. J Ophthalmic Inflamm Infect. 2019;9(1):17–30. doi: 10.1186/s12348-019-0182-y. - DOI - PMC - PubMed